Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at ...

WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through

Related Keywords

Denver ,Colorado ,United States ,Israel ,Ukraine ,American ,Gary Slatko ,Michaela Rogawski ,Dan Barber ,Stephanie Carrington ,Steve Wargacki ,Meeting Of The American Academy Neurology ,Linkedin ,Company Or Aquestive ,Aquestive Therapeutics Inc ,American Academy Of Neurology Annual Meeting ,Exchange Commission ,Drug Administration ,Nasdaq ,Company Annual Report On Form ,Buccal Film ,Annual Meeting ,American Academy ,Aquestive President ,Chief Executive ,Crossover Study Evaluating ,Diazepam From ,Buccal Film Formulation ,Children With ,Clinical Neurophysiology ,Anti Seizure Medications ,Neurology Annual Meeting ,New Drug Application ,Rectal Gel ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Aquestive Therapeutics ,Region ,